Is Anti-mullerian Hormone Level an Important Marker for Predicting Live Birth in Patients with Diminished Ovarian Reserve?

Objective: Diminished ovarian reserve (DOR) poses a significant challenge in infertility treatment.Anti-Mllerian hormone (AMH) is an important indicator of ovarian reserve and has been linked to live birth outcomes in assisted reproductive technologies (ART).This study aims to evaluate the factors most significantly impacting live birth (LB) rates in patients with DOR. Materials and Methods: This retrospective cohort study included 195 DOR patients undergoing intracytoplasmic sperm injection (ICSI) between 2020 and 2023.Patients were divided into "LB" (n=26) and "non-LB" (n=169) groups.Parameters such as age, antral follicle count (AFC), basal hormone levels, AMH, number of oocytes retrieved, embryo quality, and endometrial thickness were analyzed using univariate and multivariate logistic regression.ROC analysis was applied to assess the predictive value of these factors for LB outcomes.Results: AMH was identified as the most significant predictor of LB, with a cutoff value of 0.93 ng/mL.Other factors such as age, AFC, and endometrial thickness showed limited predictive accuracy.Frozen embryo transfer (FET) cycles were significantly associated with higher LB rates compared to fresh embryo transfers (OR=4.33,p=0.008).Conclusion: AMH levels are a key predictor of LB in DOR patients, particularly in POSEIDON 3-4 groups.The findings support the use of individualized treatment strategies, with FET being associated with improved LB outcomes in this patient population.Further research is needed to optimize ART protocols for patients with DOR.